Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study.
Identifieur interne : 001710 ( Main/Exploration ); précédent : 001709; suivant : 001711Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study.
Auteurs : Emmanuel Bachy [France] ; Jane A. Estell [Australie] ; Eric Van De Neste [Belgique] ; Réda Bouabdallah [France] ; Joan Bargay [Espagne] ; Alain Delmer [France] ; Bénédicte Gelas-Dore [France] ; Maria Gomes Da Silva [Portugal] ; Olivier Fitoussi [France] ; David Belada [République tchèque] ; Hervé Maisonneuve [France] ; Tanin Intragumtornchai [Thaïlande] ; Thierry Lamy [France] ; Peggy Dartigues [France] ; John Francis Seymour [Australie] ; Gilles Salles [France]Source :
- American journal of hematology [ 1096-8652 ] ; 2016.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Essais contrôlés randomisés comme sujet, Femelle, Grading des tumeurs, Humains, Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase (effets indésirables), Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase (usage thérapeutique), Interactions médicamenteuses, Jeune adulte, Lymphome folliculaire (diagnostic), Lymphome folliculaire (mortalité), Lymphome folliculaire (traitement médicamenteux), Modèles de hasards proportionnels, Mâle, Métastase tumorale, Pronostic, Protocoles de polychimiothérapie antinéoplasique (effets indésirables), Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique), Résultat thérapeutique, Stade de la tumeur, Sujet âgé, Sujet âgé de 80 ans ou plus, Études de cohortes.
- MESH :
- diagnostic : Lymphome folliculaire.
- effets indésirables : Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase, Protocoles de polychimiothérapie antinéoplasique.
- mortalité : Lymphome folliculaire.
- traitement médicamenteux : Lymphome folliculaire.
- usage thérapeutique : Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase, Protocoles de polychimiothérapie antinéoplasique.
- Adulte, Adulte d'âge moyen, Essais contrôlés randomisés comme sujet, Femelle, Grading des tumeurs, Humains, Interactions médicamenteuses, Jeune adulte, Modèles de hasards proportionnels, Mâle, Métastase tumorale, Pronostic, Résultat thérapeutique, Stade de la tumeur, Sujet âgé, Sujet âgé de 80 ans ou plus, Études de cohortes.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols (adverse effects), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Cohort Studies, Drug Interactions, Female, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors (adverse effects), Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use), Lymphoma, Follicular (diagnosis), Lymphoma, Follicular (drug therapy), Lymphoma, Follicular (mortality), Male, Middle Aged, Neoplasm Grading, Neoplasm Metastasis, Neoplasm Staging, Prognosis, Proportional Hazards Models, Randomized Controlled Trials as Topic, Treatment Outcome, Young Adult.
- MESH :
- chemical , adverse effects : Hydroxymethylglutaryl-CoA Reductase Inhibitors.
- adverse effects : Antineoplastic Combined Chemotherapy Protocols.
- diagnosis : Lymphoma, Follicular.
- drug therapy : Lymphoma, Follicular.
- mortality : Lymphoma, Follicular.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols, Hydroxymethylglutaryl-CoA Reductase Inhibitors.
- Adult, Aged, Aged, 80 and over, Cohort Studies, Drug Interactions, Female, Humans, Male, Middle Aged, Neoplasm Grading, Neoplasm Metastasis, Neoplasm Staging, Prognosis, Proportional Hazards Models, Randomized Controlled Trials as Topic, Treatment Outcome, Young Adult.
Abstract
An adverse prognostic impact of statin use in lymphoma was first suspected from in vitro data showing an impairment of anti-CD20 antibody binding. However, further clinical studies suggested an improved outcome associated with their use in hematological malignancies. In particular, a survival benefit was reported for patients with follicular lymphoma on statins. Our objective was to assess the outcome of follicular lymphoma patients treated in the PRIMA study with immunochemotherapy according to the use of statins. Among the 1,217 patients enrolled in the PRIMA study, 1,135 were included in the present study. Concomitant treatments at registration were available for all patients. Among those 1,135 patients, 119 were on statins (10.5%) at diagnosis. Adverse events frequencies, event-free survival (EFS), time to next lymphoma treatment (TTNLT), time to next chemotherapy (TTNCT), and overall survival (OS) were evaluated according to the use of statins. The rates of overall and specific cardiovascular adverse events between the two groups of patients were comparable both during induction and maintenance. Outcome in terms of response rates or EFS, TTNLT, TTNCT, and OS were similar regardless of the use of statins (P = 0.57, P = 0.85, P = 0.30, and P = 0.43, respectively) in univariate analysis and after further adjustments for potential confounding factors in multivariate analysis. In conclusion, statin use does not impact the prognosis of patients with follicular lymphoma treated with immunochemotherapy.
DOI: 10.1002/ajh.24305
PubMed: 26799234
Affiliations:
- Australie, Belgique, Espagne, France, Portugal, République tchèque, Thaïlande
- Aquitaine, Auvergne-Rhône-Alpes, Bohême centrale, Champagne-Ardenne, Grand Est, Nouvelle-Aquitaine, Provence-Alpes-Côte d'Azur, Rhône-Alpes, Région Bretagne, Région de Bruxelles-Capitale, Victoria (État)
- Bordeaux, Bruxelles, Lyon, Marseille, Melbourne, Prague, Reims, Rennes
- Université de Melbourne
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001E25
- to stream PubMed, to step Curation: 001E01
- to stream PubMed, to step Checkpoint: 001E01
- to stream Ncbi, to step Merge: 003036
- to stream Ncbi, to step Curation: 003036
- to stream Ncbi, to step Checkpoint: 003036
- to stream Main, to step Merge: 001705
- to stream Main, to step Curation: 001710
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study.</title><author><name sortKey="Bachy, Emmanuel" sort="Bachy, Emmanuel" uniqKey="Bachy E" first="Emmanuel" last="Bachy">Emmanuel Bachy</name><affiliation wicri:level="1"><nlm:affiliation>Hematology Department, Hôpital Lyon Sud and Université Claude Bernard, Pierre-Bénite, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hematology Department, Hôpital Lyon Sud and Université Claude Bernard, Pierre-Bénite</wicri:regionArea><wicri:noRegion>Pierre-Bénite</wicri:noRegion><wicri:noRegion>Pierre-Bénite</wicri:noRegion></affiliation></author><author><name sortKey="Estell, Jane A" sort="Estell, Jane A" uniqKey="Estell J" first="Jane A" last="Estell">Jane A. Estell</name><affiliation wicri:level="1"><nlm:affiliation>Hematology Department, Concord Hospital, Concord, NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Hematology Department, Concord Hospital, Concord, NSW</wicri:regionArea><wicri:noRegion>NSW</wicri:noRegion></affiliation></author><author><name sortKey="Van De Neste, Eric" sort="Van De Neste, Eric" uniqKey="Van De Neste E" first="Eric" last="Van De Neste">Eric Van De Neste</name><affiliation wicri:level="3"><nlm:affiliation>Hematology Department, Cliniques Universitaires UCL Saint-Luc, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Hematology Department, Cliniques Universitaires UCL Saint-Luc, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Bouabdallah, Reda" sort="Bouabdallah, Reda" uniqKey="Bouabdallah R" first="Réda" last="Bouabdallah">Réda Bouabdallah</name><affiliation wicri:level="3"><nlm:affiliation>Hematology Department, Institut Paoli Calmettes, Marseille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hematology Department, Institut Paoli Calmettes, Marseille</wicri:regionArea><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Bargay, Joan" sort="Bargay, Joan" uniqKey="Bargay J" first="Joan" last="Bargay">Joan Bargay</name><affiliation wicri:level="1"><nlm:affiliation>Hematology Department, Hospital Son Llàtzer, Palma De Mallorca, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hematology Department, Hospital Son Llàtzer, Palma De Mallorca</wicri:regionArea><wicri:noRegion>Palma De Mallorca</wicri:noRegion></affiliation></author><author><name sortKey="Delmer, Alain" sort="Delmer, Alain" uniqKey="Delmer A" first="Alain" last="Delmer">Alain Delmer</name><affiliation wicri:level="3"><nlm:affiliation>Hematology Department, CHU De Reims, Reims, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hematology Department, CHU De Reims, Reims</wicri:regionArea><placeName><region type="region">Grand Est</region><region type="old region">Champagne-Ardenne</region><settlement type="city">Reims</settlement></placeName></affiliation></author><author><name sortKey="Gelas Dore, Benedicte" sort="Gelas Dore, Benedicte" uniqKey="Gelas Dore B" first="Bénédicte" last="Gelas-Dore">Bénédicte Gelas-Dore</name><affiliation wicri:level="3"><nlm:affiliation>Deparment of Biostatistics, Lysarc, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Deparment of Biostatistics, Lysarc, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Gomes Da Silva, Maria" sort="Gomes Da Silva, Maria" uniqKey="Gomes Da Silva M" first="Maria" last="Gomes Da Silva">Maria Gomes Da Silva</name><affiliation wicri:level="1"><nlm:affiliation>Hematology Department, Portuguese Institute of Oncology, Lisbon, Portugal.</nlm:affiliation><country xml:lang="fr">Portugal</country><wicri:regionArea>Hematology Department, Portuguese Institute of Oncology, Lisbon</wicri:regionArea><wicri:noRegion>Lisbon</wicri:noRegion></affiliation></author><author><name sortKey="Fitoussi, Olivier" sort="Fitoussi, Olivier" uniqKey="Fitoussi O" first="Olivier" last="Fitoussi">Olivier Fitoussi</name><affiliation wicri:level="3"><nlm:affiliation>Hematology Department, Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hematology Department, Polyclinique Bordeaux Nord Aquitaine, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Belada, David" sort="Belada, David" uniqKey="Belada D" first="David" last="Belada">David Belada</name><affiliation wicri:level="3"><nlm:affiliation>Hematology Department, University Hospital Hradec Kràlové, Prague, Czech Republic.</nlm:affiliation><country xml:lang="fr">République tchèque</country><wicri:regionArea>Hematology Department, University Hospital Hradec Kràlové, Prague</wicri:regionArea><placeName><settlement type="city">Prague</settlement><region type="région" nuts="2">Bohême centrale</region></placeName></affiliation></author><author><name sortKey="Maisonneuve, Herve" sort="Maisonneuve, Herve" uniqKey="Maisonneuve H" first="Hervé" last="Maisonneuve">Hervé Maisonneuve</name><affiliation wicri:level="1"><nlm:affiliation>Hematology Department, Centre Hospitalier De La Roche Sur Yon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hematology Department, Centre Hospitalier De La Roche Sur Yon</wicri:regionArea><wicri:noRegion>Centre Hospitalier De La Roche Sur Yon</wicri:noRegion><wicri:noRegion>Centre Hospitalier De La Roche Sur Yon</wicri:noRegion></affiliation></author><author><name sortKey="Intragumtornchai, Tanin" sort="Intragumtornchai, Tanin" uniqKey="Intragumtornchai T" first="Tanin" last="Intragumtornchai">Tanin Intragumtornchai</name><affiliation wicri:level="1"><nlm:affiliation>Hematology Department, Chulalongkorn University, Bangkok, Thailand.</nlm:affiliation><country xml:lang="fr">Thaïlande</country><wicri:regionArea>Hematology Department, Chulalongkorn University, Bangkok</wicri:regionArea><wicri:noRegion>Bangkok</wicri:noRegion></affiliation></author><author><name sortKey="Lamy, Thierry" sort="Lamy, Thierry" uniqKey="Lamy T" first="Thierry" last="Lamy">Thierry Lamy</name><affiliation wicri:level="3"><nlm:affiliation>Hematology Department, Centre Hospitalier Pontchaillou, Rennes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hematology Department, Centre Hospitalier Pontchaillou, Rennes</wicri:regionArea><placeName><region type="region">Région Bretagne</region><region type="old region">Région Bretagne</region><settlement type="city">Rennes</settlement></placeName></affiliation></author><author><name sortKey="Dartigues, Peggy" sort="Dartigues, Peggy" uniqKey="Dartigues P" first="Peggy" last="Dartigues">Peggy Dartigues</name><affiliation wicri:level="1"><nlm:affiliation>Hematology Department, Institut Gustave Roussy, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hematology Department, Institut Gustave Roussy, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><wicri:noRegion>Villejuif</wicri:noRegion></affiliation></author><author><name sortKey="Seymour, John Francis" sort="Seymour, John Francis" uniqKey="Seymour J" first="John Francis" last="Seymour">John Francis Seymour</name><affiliation wicri:level="4"><nlm:affiliation>Hematology Department, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, VIC, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Hematology Department, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, VIC</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Salles, Gilles" sort="Salles, Gilles" uniqKey="Salles G" first="Gilles" last="Salles">Gilles Salles</name><affiliation wicri:level="1"><nlm:affiliation>Hematology Department, Hôpital Lyon Sud and Université Claude Bernard, Pierre-Bénite, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hematology Department, Hôpital Lyon Sud and Université Claude Bernard, Pierre-Bénite</wicri:regionArea><wicri:noRegion>Pierre-Bénite</wicri:noRegion><wicri:noRegion>Pierre-Bénite</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26799234</idno><idno type="pmid">26799234</idno><idno type="doi">10.1002/ajh.24305</idno><idno type="wicri:Area/PubMed/Corpus">001E25</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001E25</idno><idno type="wicri:Area/PubMed/Curation">001E01</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001E01</idno><idno type="wicri:Area/PubMed/Checkpoint">001E01</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001E01</idno><idno type="wicri:Area/Ncbi/Merge">003036</idno><idno type="wicri:Area/Ncbi/Curation">003036</idno><idno type="wicri:Area/Ncbi/Checkpoint">003036</idno><idno type="wicri:Area/Main/Merge">001705</idno><idno type="wicri:Area/Main/Curation">001710</idno><idno type="wicri:Area/Main/Exploration">001710</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study.</title><author><name sortKey="Bachy, Emmanuel" sort="Bachy, Emmanuel" uniqKey="Bachy E" first="Emmanuel" last="Bachy">Emmanuel Bachy</name><affiliation wicri:level="1"><nlm:affiliation>Hematology Department, Hôpital Lyon Sud and Université Claude Bernard, Pierre-Bénite, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hematology Department, Hôpital Lyon Sud and Université Claude Bernard, Pierre-Bénite</wicri:regionArea><wicri:noRegion>Pierre-Bénite</wicri:noRegion><wicri:noRegion>Pierre-Bénite</wicri:noRegion></affiliation></author><author><name sortKey="Estell, Jane A" sort="Estell, Jane A" uniqKey="Estell J" first="Jane A" last="Estell">Jane A. Estell</name><affiliation wicri:level="1"><nlm:affiliation>Hematology Department, Concord Hospital, Concord, NSW, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Hematology Department, Concord Hospital, Concord, NSW</wicri:regionArea><wicri:noRegion>NSW</wicri:noRegion></affiliation></author><author><name sortKey="Van De Neste, Eric" sort="Van De Neste, Eric" uniqKey="Van De Neste E" first="Eric" last="Van De Neste">Eric Van De Neste</name><affiliation wicri:level="3"><nlm:affiliation>Hematology Department, Cliniques Universitaires UCL Saint-Luc, Brussels, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Hematology Department, Cliniques Universitaires UCL Saint-Luc, Brussels</wicri:regionArea><placeName><settlement type="city">Bruxelles</settlement><region nuts="2">Région de Bruxelles-Capitale</region></placeName></affiliation></author><author><name sortKey="Bouabdallah, Reda" sort="Bouabdallah, Reda" uniqKey="Bouabdallah R" first="Réda" last="Bouabdallah">Réda Bouabdallah</name><affiliation wicri:level="3"><nlm:affiliation>Hematology Department, Institut Paoli Calmettes, Marseille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hematology Department, Institut Paoli Calmettes, Marseille</wicri:regionArea><placeName><region type="region">Provence-Alpes-Côte d'Azur</region><region type="old region">Provence-Alpes-Côte d'Azur</region><settlement type="city">Marseille</settlement></placeName></affiliation></author><author><name sortKey="Bargay, Joan" sort="Bargay, Joan" uniqKey="Bargay J" first="Joan" last="Bargay">Joan Bargay</name><affiliation wicri:level="1"><nlm:affiliation>Hematology Department, Hospital Son Llàtzer, Palma De Mallorca, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Hematology Department, Hospital Son Llàtzer, Palma De Mallorca</wicri:regionArea><wicri:noRegion>Palma De Mallorca</wicri:noRegion></affiliation></author><author><name sortKey="Delmer, Alain" sort="Delmer, Alain" uniqKey="Delmer A" first="Alain" last="Delmer">Alain Delmer</name><affiliation wicri:level="3"><nlm:affiliation>Hematology Department, CHU De Reims, Reims, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hematology Department, CHU De Reims, Reims</wicri:regionArea><placeName><region type="region">Grand Est</region><region type="old region">Champagne-Ardenne</region><settlement type="city">Reims</settlement></placeName></affiliation></author><author><name sortKey="Gelas Dore, Benedicte" sort="Gelas Dore, Benedicte" uniqKey="Gelas Dore B" first="Bénédicte" last="Gelas-Dore">Bénédicte Gelas-Dore</name><affiliation wicri:level="3"><nlm:affiliation>Deparment of Biostatistics, Lysarc, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Deparment of Biostatistics, Lysarc, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Gomes Da Silva, Maria" sort="Gomes Da Silva, Maria" uniqKey="Gomes Da Silva M" first="Maria" last="Gomes Da Silva">Maria Gomes Da Silva</name><affiliation wicri:level="1"><nlm:affiliation>Hematology Department, Portuguese Institute of Oncology, Lisbon, Portugal.</nlm:affiliation><country xml:lang="fr">Portugal</country><wicri:regionArea>Hematology Department, Portuguese Institute of Oncology, Lisbon</wicri:regionArea><wicri:noRegion>Lisbon</wicri:noRegion></affiliation></author><author><name sortKey="Fitoussi, Olivier" sort="Fitoussi, Olivier" uniqKey="Fitoussi O" first="Olivier" last="Fitoussi">Olivier Fitoussi</name><affiliation wicri:level="3"><nlm:affiliation>Hematology Department, Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hematology Department, Polyclinique Bordeaux Nord Aquitaine, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Belada, David" sort="Belada, David" uniqKey="Belada D" first="David" last="Belada">David Belada</name><affiliation wicri:level="3"><nlm:affiliation>Hematology Department, University Hospital Hradec Kràlové, Prague, Czech Republic.</nlm:affiliation><country xml:lang="fr">République tchèque</country><wicri:regionArea>Hematology Department, University Hospital Hradec Kràlové, Prague</wicri:regionArea><placeName><settlement type="city">Prague</settlement><region type="région" nuts="2">Bohême centrale</region></placeName></affiliation></author><author><name sortKey="Maisonneuve, Herve" sort="Maisonneuve, Herve" uniqKey="Maisonneuve H" first="Hervé" last="Maisonneuve">Hervé Maisonneuve</name><affiliation wicri:level="1"><nlm:affiliation>Hematology Department, Centre Hospitalier De La Roche Sur Yon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hematology Department, Centre Hospitalier De La Roche Sur Yon</wicri:regionArea><wicri:noRegion>Centre Hospitalier De La Roche Sur Yon</wicri:noRegion><wicri:noRegion>Centre Hospitalier De La Roche Sur Yon</wicri:noRegion></affiliation></author><author><name sortKey="Intragumtornchai, Tanin" sort="Intragumtornchai, Tanin" uniqKey="Intragumtornchai T" first="Tanin" last="Intragumtornchai">Tanin Intragumtornchai</name><affiliation wicri:level="1"><nlm:affiliation>Hematology Department, Chulalongkorn University, Bangkok, Thailand.</nlm:affiliation><country xml:lang="fr">Thaïlande</country><wicri:regionArea>Hematology Department, Chulalongkorn University, Bangkok</wicri:regionArea><wicri:noRegion>Bangkok</wicri:noRegion></affiliation></author><author><name sortKey="Lamy, Thierry" sort="Lamy, Thierry" uniqKey="Lamy T" first="Thierry" last="Lamy">Thierry Lamy</name><affiliation wicri:level="3"><nlm:affiliation>Hematology Department, Centre Hospitalier Pontchaillou, Rennes, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hematology Department, Centre Hospitalier Pontchaillou, Rennes</wicri:regionArea><placeName><region type="region">Région Bretagne</region><region type="old region">Région Bretagne</region><settlement type="city">Rennes</settlement></placeName></affiliation></author><author><name sortKey="Dartigues, Peggy" sort="Dartigues, Peggy" uniqKey="Dartigues P" first="Peggy" last="Dartigues">Peggy Dartigues</name><affiliation wicri:level="1"><nlm:affiliation>Hematology Department, Institut Gustave Roussy, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hematology Department, Institut Gustave Roussy, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><wicri:noRegion>Villejuif</wicri:noRegion></affiliation></author><author><name sortKey="Seymour, John Francis" sort="Seymour, John Francis" uniqKey="Seymour J" first="John Francis" last="Seymour">John Francis Seymour</name><affiliation wicri:level="4"><nlm:affiliation>Hematology Department, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, VIC, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Hematology Department, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, VIC</wicri:regionArea><orgName type="university">Université de Melbourne</orgName><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Salles, Gilles" sort="Salles, Gilles" uniqKey="Salles G" first="Gilles" last="Salles">Gilles Salles</name><affiliation wicri:level="1"><nlm:affiliation>Hematology Department, Hôpital Lyon Sud and Université Claude Bernard, Pierre-Bénite, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Hematology Department, Hôpital Lyon Sud and Université Claude Bernard, Pierre-Bénite</wicri:regionArea><wicri:noRegion>Pierre-Bénite</wicri:noRegion><wicri:noRegion>Pierre-Bénite</wicri:noRegion></affiliation></author></analytic><series><title level="j">American journal of hematology</title><idno type="eISSN">1096-8652</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antineoplastic Combined Chemotherapy Protocols (adverse effects)</term><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Cohort Studies</term><term>Drug Interactions</term><term>Female</term><term>Humans</term><term>Hydroxymethylglutaryl-CoA Reductase Inhibitors (adverse effects)</term><term>Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use)</term><term>Lymphoma, Follicular (diagnosis)</term><term>Lymphoma, Follicular (drug therapy)</term><term>Lymphoma, Follicular (mortality)</term><term>Male</term><term>Middle Aged</term><term>Neoplasm Grading</term><term>Neoplasm Metastasis</term><term>Neoplasm Staging</term><term>Prognosis</term><term>Proportional Hazards Models</term><term>Randomized Controlled Trials as Topic</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Essais contrôlés randomisés comme sujet</term><term>Femelle</term><term>Grading des tumeurs</term><term>Humains</term><term>Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase (effets indésirables)</term><term>Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase (usage thérapeutique)</term><term>Interactions médicamenteuses</term><term>Jeune adulte</term><term>Lymphome folliculaire (diagnostic)</term><term>Lymphome folliculaire (mortalité)</term><term>Lymphome folliculaire (traitement médicamenteux)</term><term>Modèles de hasards proportionnels</term><term>Mâle</term><term>Métastase tumorale</term><term>Pronostic</term><term>Protocoles de polychimiothérapie antinéoplasique (effets indésirables)</term><term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term><term>Résultat thérapeutique</term><term>Stade de la tumeur</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Études de cohortes</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Lymphoma, Follicular</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Lymphome folliculaire</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Lymphoma, Follicular</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase</term><term>Protocoles de polychimiothérapie antinéoplasique</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Lymphoma, Follicular</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Lymphome folliculaire</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term><term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Lymphome folliculaire</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase</term><term>Protocoles de polychimiothérapie antinéoplasique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Cohort Studies</term><term>Drug Interactions</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neoplasm Grading</term><term>Neoplasm Metastasis</term><term>Neoplasm Staging</term><term>Prognosis</term><term>Proportional Hazards Models</term><term>Randomized Controlled Trials as Topic</term><term>Treatment Outcome</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Essais contrôlés randomisés comme sujet</term><term>Femelle</term><term>Grading des tumeurs</term><term>Humains</term><term>Interactions médicamenteuses</term><term>Jeune adulte</term><term>Modèles de hasards proportionnels</term><term>Mâle</term><term>Métastase tumorale</term><term>Pronostic</term><term>Résultat thérapeutique</term><term>Stade de la tumeur</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Études de cohortes</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">An adverse prognostic impact of statin use in lymphoma was first suspected from in vitro data showing an impairment of anti-CD20 antibody binding. However, further clinical studies suggested an improved outcome associated with their use in hematological malignancies. In particular, a survival benefit was reported for patients with follicular lymphoma on statins. Our objective was to assess the outcome of follicular lymphoma patients treated in the PRIMA study with immunochemotherapy according to the use of statins. Among the 1,217 patients enrolled in the PRIMA study, 1,135 were included in the present study. Concomitant treatments at registration were available for all patients. Among those 1,135 patients, 119 were on statins (10.5%) at diagnosis. Adverse events frequencies, event-free survival (EFS), time to next lymphoma treatment (TTNLT), time to next chemotherapy (TTNCT), and overall survival (OS) were evaluated according to the use of statins. The rates of overall and specific cardiovascular adverse events between the two groups of patients were comparable both during induction and maintenance. Outcome in terms of response rates or EFS, TTNLT, TTNCT, and OS were similar regardless of the use of statins (P = 0.57, P = 0.85, P = 0.30, and P = 0.43, respectively) in univariate analysis and after further adjustments for potential confounding factors in multivariate analysis. In conclusion, statin use does not impact the prognosis of patients with follicular lymphoma treated with immunochemotherapy.</div></front></TEI><affiliations><list><country><li>Australie</li><li>Belgique</li><li>Espagne</li><li>France</li><li>Portugal</li><li>République tchèque</li><li>Thaïlande</li></country><region><li>Aquitaine</li><li>Auvergne-Rhône-Alpes</li><li>Bohême centrale</li><li>Champagne-Ardenne</li><li>Grand Est</li><li>Nouvelle-Aquitaine</li><li>Provence-Alpes-Côte d'Azur</li><li>Rhône-Alpes</li><li>Région Bretagne</li><li>Région de Bruxelles-Capitale</li><li>Victoria (État)</li></region><settlement><li>Bordeaux</li><li>Bruxelles</li><li>Lyon</li><li>Marseille</li><li>Melbourne</li><li>Prague</li><li>Reims</li><li>Rennes</li></settlement><orgName><li>Université de Melbourne</li></orgName></list><tree><country name="France"><noRegion><name sortKey="Bachy, Emmanuel" sort="Bachy, Emmanuel" uniqKey="Bachy E" first="Emmanuel" last="Bachy">Emmanuel Bachy</name></noRegion><name sortKey="Bouabdallah, Reda" sort="Bouabdallah, Reda" uniqKey="Bouabdallah R" first="Réda" last="Bouabdallah">Réda Bouabdallah</name><name sortKey="Dartigues, Peggy" sort="Dartigues, Peggy" uniqKey="Dartigues P" first="Peggy" last="Dartigues">Peggy Dartigues</name><name sortKey="Delmer, Alain" sort="Delmer, Alain" uniqKey="Delmer A" first="Alain" last="Delmer">Alain Delmer</name><name sortKey="Fitoussi, Olivier" sort="Fitoussi, Olivier" uniqKey="Fitoussi O" first="Olivier" last="Fitoussi">Olivier Fitoussi</name><name sortKey="Gelas Dore, Benedicte" sort="Gelas Dore, Benedicte" uniqKey="Gelas Dore B" first="Bénédicte" last="Gelas-Dore">Bénédicte Gelas-Dore</name><name sortKey="Lamy, Thierry" sort="Lamy, Thierry" uniqKey="Lamy T" first="Thierry" last="Lamy">Thierry Lamy</name><name sortKey="Maisonneuve, Herve" sort="Maisonneuve, Herve" uniqKey="Maisonneuve H" first="Hervé" last="Maisonneuve">Hervé Maisonneuve</name><name sortKey="Salles, Gilles" sort="Salles, Gilles" uniqKey="Salles G" first="Gilles" last="Salles">Gilles Salles</name></country><country name="Australie"><noRegion><name sortKey="Estell, Jane A" sort="Estell, Jane A" uniqKey="Estell J" first="Jane A" last="Estell">Jane A. Estell</name></noRegion><name sortKey="Seymour, John Francis" sort="Seymour, John Francis" uniqKey="Seymour J" first="John Francis" last="Seymour">John Francis Seymour</name></country><country name="Belgique"><region name="Région de Bruxelles-Capitale"><name sortKey="Van De Neste, Eric" sort="Van De Neste, Eric" uniqKey="Van De Neste E" first="Eric" last="Van De Neste">Eric Van De Neste</name></region></country><country name="Espagne"><noRegion><name sortKey="Bargay, Joan" sort="Bargay, Joan" uniqKey="Bargay J" first="Joan" last="Bargay">Joan Bargay</name></noRegion></country><country name="Portugal"><noRegion><name sortKey="Gomes Da Silva, Maria" sort="Gomes Da Silva, Maria" uniqKey="Gomes Da Silva M" first="Maria" last="Gomes Da Silva">Maria Gomes Da Silva</name></noRegion></country><country name="République tchèque"><region name="Bohême centrale"><name sortKey="Belada, David" sort="Belada, David" uniqKey="Belada D" first="David" last="Belada">David Belada</name></region></country><country name="Thaïlande"><noRegion><name sortKey="Intragumtornchai, Tanin" sort="Intragumtornchai, Tanin" uniqKey="Intragumtornchai T" first="Tanin" last="Intragumtornchai">Tanin Intragumtornchai</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001710 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001710 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26799234
|texte= Statin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: An exploratory analysis of the PRIMA cohort study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26799234" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |